InnoCare Pharma Ltd.

“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included

Innovent Biologics, Inc. , Transcenta Holding Ltd. and Shanghai Henlius Biotech Co. Ltd. are leading Chinese drug makers’ latest efforts to extend the high-stakes undertaking of global pivotal Pha